

AMENDMENTS TO THE CLAIMS


Please cancel claims 1-23 and 29-32 without prejudice.

Pursuant to 37 C.F.R. § 1.121(c)(1), please amend claim 1.

Please add new claims 33-{.

Claims 1-23 (**Cancelled**)

24. (Original) A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR7, -SR7, a halogen or -N(R9)R10;

R9 and R10, each independently, represent -H, alkyl, alkenyl, -(CH₂)_n-R7, or R9 and R10, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R7 represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle;

wherein the ligand V comprises W, Y, and a heterocycle having from 4 to about 8 atoms in the ring structure, optionally aromatic and optionally substituted. a heterocycle, optionally aromatic and optionally substituted, that comprises the atoms W and Y and has from 4 to about 8 atoms in the ring structure.

25. (Original) The coordination complex of claim 24, wherein W is N.

26. (Original) The coordination complex of claim 24, wherein Pt is Pt(II).

27. (Original) A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 24 and a pharmaceutically acceptable carrier.

28. (Original) The pharmaceutical composition of claim 27, wherein said coordination complex is ammine(2-amino-3-picoline)dichloroplatinum(II).

Claims 29-32 (Cancelled)

33. (New) The coordination complex of claim 24, wherein V is a 6-membered aromatic heterocycle.

34. (New) The coordination complex of claim 33, wherein V is pyridine or a substituted pyridine.

35. (New) The coordination complex of claim 33, wherein V is picoline or a substituted picoline.

36. (New) The coordination complex of claim 24, wherein Pt is Pt(IV) and two additional ligands in the trans axial positions are present.

37. (New) The coordination complex of claim 36, wherein said each of said additional ligands comprise a carboxylate group.

38. (New) A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 36 and a pharmaceutically acceptable carrier.

39. (New) The pharmaceutical composition of claim 38, wherein said coordination complex is ammine(2-amino-3-picoline)dichlorodiacetoplatinum(IV).

40. (New) The coordination complex of claim 24, wherein both X are halogens.

41. (New) The coordination complex of claim 40, wherein said halogen is chlorine.

42. (New) The coordination complex of claim 24, wherein both X comprise a carboxylate group.

43. (New) The coordination complex of claim 42, wherein said carboxylate group is a chelating dicarboxylate.


44. (New) The coordination complex of claim 42, wherein at least one X is acetate.

45. (New) The coordination complex of claim 24, wherein L is an amine having the structure NR₂(R₃), wherein R₂ and R₃ each independently represent a hydrogen, an alkyl, an alkenyl, -

$(CH_2)_m$ -R4, or R2 and R3, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; and wherein R2 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8.

46. (New) The coordination complex of claim 24, wherein L is an ammine.

47. (New) A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR7, -SR7, a halogen or -N(R9)R10;

R9 and R10, each independently, represent -H, alkyl, alkenyl, $-(CH_2)_n$ -R7, or R9 and R10, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R7 represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle;


wherein the ligand V comprises a heterocycle, optionally aromatic and optionally substituted, that comprises the atoms W and Y and has from 4 to about 8 atoms in the ring structure.

48. (New) The coordination complex of claim 47, wherein each of X is a halogen.

49. (New) The coordination complex of claim 48, wherein said halogen is chlorine.

50. (New) A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 47 and a pharmaceutically acceptable carrier.

51. (New) A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR7, -SR7, a halogen or -N(R9)R10;

R9 and R10, each independently, represent -H, alkyl, alkenyl, -(CH2)n-R7, or R9 and R10, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R7 represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle;

wherein the ligand V comprises a heterocycle, optionally aromatic and optionally substituted, that comprises the atoms W and Y and has from 4 to about 8 atoms in the ring structure.

52. (New) A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 51 and a pharmaceutically acceptable carrier.